Reconstruction of the binding pathway of an anti-HIV drug, Indinavir, in complex with the HTLV-1 protease by Unaggregated Unbiased Molecular Dynamics simulation
Abstract
Retroviruses are a growing concern for the health of human beings, and one of the dangerous members of this family is the Human T-cell Leukemia Virus 1 (HTLV-1) virus. It has affected more than 20 million people so far, and since there are no registered treatments against it yet, urgent treatment solutions are needed. One of the most promising drug targets to fight this virus is the protease enzyme of the viruss protein machinery. In this study, by utilizing a computational method called Unaggregated Unbiased Molecular Dynamics (UUMD), we reconstructed the binding pathway of a HTLV-1 protease inhibitor, Indinavir, to find the details of the binding pathway, the influential residues, and also the stable states of the binding pathway. We achieved the native conformation of the inhibitor in 6 rounds, 360 replicas by performing over 4 micro-seconds of UMD simulations. We found 3 Intermediate states between the solvated state and the native conformation state in the binding pathway. We also discovered that aromatic residues such as Trp98 and Trp98', catalytic residues Asp32 and Asp32', and the flap regions residues have the most influential roles in the binding pathway and also have the most contribution to the total interaction energies. We believe that the details found in this study would be a great guide for developing new treatment solutions against the HTLV-1 virus by inhibiting the HTLV-1 protease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 0.53
- Field percentile
- top 35%
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by Supervised Molecular Dynamics simulation
Farzin Sohraby, Hassan Aryapour·PLoS ONEPeer-reviewed·Sep 27, 2021
- Comparative study of the unbinding process of some HTLV-1 protease inhibitors using Unbiased Molecular Dynamics simulation
Fereshteh Noroozi Tiyoula, Hassan Aryapour, Mostafa Javaheri Moghadam·PLoS ONEPeer-reviewed·Jul 14, 2022
- Pathway Specific Unbinding Free Energy Profiles of Ritonavir Dissociation From HIV-1 Protease
Emily Vig, Jianan Sun, Chia‐en A. Chang·BiochemistryPeer-reviewed·Feb 10, 2025
- Structure-Based Pharmacophore Modeling, High-throughput Screening, and Molecular Dynamics Identify a Novel DrugBank-Derived HIV-1 Protease Inhibitor
Ali Sultan Khazaal Nazal, Amjed Majid Rashid Alrashedi, … Mustafa Abdulkadhim Hussein Ali Rabeea·PLoS ONEPeer-reviewed·Jun 12, 2026
- HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
J. S. O'Donnell, N. Tardiota, … K. J. Chappell·bioRxiv·May 25, 2023
- In silico approach on drug repurposing - Antimalarial drugs against HIV-1 protease
CHARLI DEEPAK ARULANANDAM·bioRxiv·Jan 12, 2021